CN1216635C - 治疗糖尿病的组合物与方法 - Google Patents

治疗糖尿病的组合物与方法 Download PDF

Info

Publication number
CN1216635C
CN1216635C CN988079313A CN98807931A CN1216635C CN 1216635 C CN1216635 C CN 1216635C CN 988079313 A CN988079313 A CN 988079313A CN 98807931 A CN98807931 A CN 98807931A CN 1216635 C CN1216635 C CN 1216635C
Authority
CN
China
Prior art keywords
compositions
zinc
arachidonic acid
histidine
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN988079313A
Other languages
English (en)
Chinese (zh)
Other versions
CN1265560A (zh
Inventor
穆恩·K·桑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wenbao Medicine Co ltd
Original Assignee
Wenbao Medicine Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wenbao Medicine Co ltd filed Critical Wenbao Medicine Co ltd
Publication of CN1265560A publication Critical patent/CN1265560A/zh
Application granted granted Critical
Publication of CN1216635C publication Critical patent/CN1216635C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CN988079313A 1997-08-11 1998-08-06 治疗糖尿病的组合物与方法 Expired - Fee Related CN1216635C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/909,240 US5834032A (en) 1997-08-11 1997-08-11 Compositions and methods for treating diabetes
US08/909,240 1997-08-11

Publications (2)

Publication Number Publication Date
CN1265560A CN1265560A (zh) 2000-09-06
CN1216635C true CN1216635C (zh) 2005-08-31

Family

ID=25426873

Family Applications (1)

Application Number Title Priority Date Filing Date
CN988079313A Expired - Fee Related CN1216635C (zh) 1997-08-11 1998-08-06 治疗糖尿病的组合物与方法

Country Status (6)

Country Link
US (1) US5834032A (enExample)
JP (1) JP2001513487A (enExample)
KR (1) KR100533618B1 (enExample)
CN (1) CN1216635C (enExample)
AU (1) AU8693098A (enExample)
WO (1) WO1999007224A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111246859A (zh) * 2017-10-20 2020-06-05 诺麦塔制药有限公司 含有锌盐、环二肽-组氨酸脯氨酸及作为有效成分的抗糖尿药物的糖尿病预防或治疗用药学组合物

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750336A (en) * 1994-02-10 1998-05-12 The Salk Institute For Biological Studies Assays for the identification of compounds which inhibit activation of cAMP and mitogen responsive genes
WO2000018392A1 (en) * 1998-09-25 2000-04-06 Glycox Corporation Limited Fructosamine oxidase: antagonists and inhibitors
JP2001220348A (ja) * 1999-11-30 2001-08-14 Japan Science & Technology Corp 亜鉛（ｉｉ）有機錯体からなる血糖降下剤
JP5048201B2 (ja) 2000-08-04 2012-10-17 ディーエムアイ バイオサイエンシズ インコーポレイテッド ジケトピペラジン類の使用方法とジケトピペラジン類を含む組成物
JP4161031B2 (ja) * 2000-10-31 2008-10-08 独立行政法人産業技術総合研究所 亜鉛含有リン酸カルシウム微粒子含有懸濁液または粒子溶媒混合系及び亜鉛欠乏症治療剤
JP2003040784A (ja) * 2001-01-31 2003-02-13 Japan Science & Technology Corp 血糖降下剤
DK1571970T3 (da) * 2002-10-02 2011-11-28 Dmi Biosciences Inc Diagnose og monitorering af sygdomme
US6989025B2 (en) * 2002-10-04 2006-01-24 Boston Scientific Scimed, Inc. Extruded tubing with discontinuous striping
US7524517B2 (en) * 2003-01-17 2009-04-28 Uab Research Foundation Methods and compositions for P2X receptor calcium entry channels and other calcium entry mechanisms
DE602004011275T2 (de) * 2003-01-31 2009-01-15 Moon K. Northridge Song Zusammensetzungen und Verfahren zur Behandlung von Fettleibigkeit
CN102210852B (zh) 2003-05-15 2016-10-19 安皮奥制药股份有限公司 T-细胞介导的疾病的治疗
JP2008538547A (ja) * 2005-03-09 2008-10-30 ロジャー・ウィリアムズ・ホスピタル 甲状腺刺激ホルモン放出ホルモン類縁体及び使用方法
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
KR101530050B1 (ko) * 2007-03-02 2015-06-22 주식회사 노브메타파마 알츠하이머 질환 및 치매를 치료하기 위한 조성물 및 방법
JP5856843B2 (ja) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド ジケトピペラジンを用いた医薬組成物
EP2613786A4 (en) 2010-09-07 2013-10-23 Dmi Acquisition Corp TREATMENT OF DISEASES
JP2014530063A (ja) 2011-10-10 2014-11-17 アンピオ ファーマシューティカルズ，インコーポレイテッド 免疫寛容が高められた埋込み型医療用デバイス、ならびに製造方法および埋込み方法
PH12014500685B1 (en) 2011-10-10 2018-10-03 Ampio Pharmaceuticals Inc Treatment of degenerative joint disease
HK1198812A1 (en) 2011-10-28 2015-06-12 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
CA2906864A1 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
CN106456633A (zh) * 2014-06-20 2017-02-22 三得利控股株式会社 糖代谢改善剂
EP4066836A1 (en) 2014-08-18 2022-10-05 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
EP3310375A4 (en) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. USE OF LOW-MOLECULAR FRACTIONS OF HUMAN SERUMALBUMINE IN THE TREATMENT OF ILLNESSES
CN105748564A (zh) * 2015-12-21 2016-07-13 天津中津药业股份有限公司 一种治疗糖尿病的药物组合物
WO2019098811A2 (ko) * 2017-11-20 2019-05-23 주식회사 노브메타파마 Chp(시클로-히스프로)를 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물
US20210177932A1 (en) * 2017-12-11 2021-06-17 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for prevention and treatment of immune deficiency and inflammation
KR20190074746A (ko) * 2017-12-20 2019-06-28 주식회사 노브메타파마 시클로-히스프로를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약제학적 제제
US20200345728A1 (en) * 2019-04-30 2020-11-05 Novmetapharma Co., Ltd. Compositions and methods for treatment of atherosclerosis
KR102115353B1 (ko) * 2019-05-17 2020-05-26 주식회사 노브메타파마 Chp(사이클로-히스프로) 및 부갑상선 호르몬을 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물
ES2972490T3 (es) * 2019-12-20 2024-06-13 Vector Vitale Ip Llc Composición y método para el tratamiento de la diabetes de tipo I
KR20230025709A (ko) 2020-06-17 2023-02-22 주식회사 노브메타파마 바이러스 감염을 치료하기 위한 조성물 및 방법
BR112023003263A2 (pt) 2020-09-04 2023-03-21 Nestle Sa Composições e métodos para fornecer benefícios de saúde a um animal
KR20240032221A (ko) * 2022-08-31 2024-03-12 주식회사 노브메타파마 아연염 및 사이클로-히스프로를 유효성분으로 포함하는 호흡기 질환의 예방, 개선 또는 치료용 조성물
KR20250066976A (ko) 2023-11-07 2025-05-14 주식회사 노브메타파마 아연염 및 사이클로-히스프로를 유효성분으로 포함하는 당뇨병성 신증의 예방, 개선 또는 치료용 조성물
KR20250076353A (ko) 2023-11-21 2025-05-29 주식회사 노브메타파마 글루콘산 아연염 및 사이클로-히스프로를 유효성분으로 포함하는 비만 및 당뇨병의 예방, 개선 또는 치료용 조성물

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111246859A (zh) * 2017-10-20 2020-06-05 诺麦塔制药有限公司 含有锌盐、环二肽-组氨酸脯氨酸及作为有效成分的抗糖尿药物的糖尿病预防或治疗用药学组合物
CN111246859B (zh) * 2017-10-20 2022-05-03 诺麦塔制药有限公司 含有锌盐、环二肽-组氨酸脯氨酸及作为有效成分的抗糖尿药物的糖尿病预防或治疗用药学组合物

Also Published As

Publication number Publication date
HK1031174A1 (en) 2001-06-08
KR20010022786A (ko) 2001-03-26
WO1999007224A1 (en) 1999-02-18
CN1265560A (zh) 2000-09-06
JP2001513487A (ja) 2001-09-04
KR100533618B1 (ko) 2005-12-06
US5834032A (en) 1998-11-10
AU8693098A (en) 1999-03-01

Similar Documents

Publication Publication Date Title
CN1265560A (zh) 治疗糖尿病的组成物与方法
CN1234414C (zh) 糖尿病性合并症和神经障碍用的药剂及其应用
US20240058353A1 (en) Methods for treating gi tract disorders
JP2000501707A (ja) グリシン捕捉性アンタゴニストを用いる拒絶性および認知性精神分裂病症候群の処置
WO2011085216A2 (en) Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
US20140271890A1 (en) Controlled-release pharmaceutical composition
US12533333B2 (en) Method of treatment of obesity
JP5166437B2 (ja) カヘキシーの治療
JPH07116048B2 (ja) パーキンソン症候群の治療用薬剤
CN114786647A (zh) 口服药学立即释放组合物和用于重量减轻的治疗方法
CN1708297A (zh) 用于预防和/或治疗抗癌剂诱导的外周神经病的乙酰基－l－肉碱
CN101056641A (zh) 治疗潮红的s－米氮平
JP2008509170A (ja) カルビドパ／ベンセラジドを含むｌ−トリプトファンの新規製剤
CN1346278A (zh) 麻醉的调节
HK1031174B (en) Compositions and methods for treating diabetes
CN1856300A (zh) 治疗与代谢紊乱相关的状况的方法和材料
CN110327321A (zh) 对饮酒导致中枢神经突触可塑性改变具有解救作用氨基酸的应用
US20050009919A1 (en) Treating cachexia and excessive catabolism with (-)-hydroxycitric acid
WO2024049497A1 (en) Pharmaceutical compositions of d10-docosahexaenoic acid or esters thereof
CN1845727A (zh) 使用酒精和精神活性物质期间应用的治疗和预防剂
Liebowitz depression: effects of the alpha 2-adrenergic agonist clonidine. Siever
AU2001296493A1 (en) Use of neuropeptide-Y antagonists in treatment of alcoholism
MXPA00010998A (en) Novel fatty analogues for the treatment of diabetes
HK1216848B (en) Methods for treating gi tract disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1057950

Country of ref document: HK

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee